WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007002512) NEUROPROTECTIVE EFFECTIVE COMPOUND
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/002512    International Application No.:    PCT/US2006/024656
Publication Date: 04.01.2007 International Filing Date: 23.06.2006
IPC:
A61K 48/00 (2006.01)
Applicants: TISSUEGENE, INC. [US/US]; 209 Perry Parkway, Suite 13, Gaithersburg, MD 20877 (US) (For All Designated States Except US).
LEE, Kwan, Hee [KR/US]; (US) (For US Only).
LEE, Duk, Keun [KR/US]; (US) (For US Only).
YI, Youngsuk [KR/US]; (US) (For US Only).
NOH, Moon, Jong [KR/US]; (US) (For US Only).
KIM, Hyoung, Chun [KR/KR]; (KR) (For US Only)
Inventors: LEE, Kwan, Hee; (US).
LEE, Duk, Keun; (US).
YI, Youngsuk; (US).
NOH, Moon, Jong; (US).
KIM, Hyoung, Chun; (KR)
Agent: KIM, Joseph, Hyosuk; JHK Law, P.O. Box 1078, La Canada, CA 91012-1078 (US)
Priority Data:
60/595,342 23.06.2005 US
Title (EN) NEUROPROTECTIVE EFFECTIVE COMPOUND
(FR) COMPOSE NEUROPROTECTEUR EFFICACE
Abstract: front page image
(EN)The present application discloses a method of preventing degeneration of nerve, which includes: a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily or neurotrophic factor proteins operatively linked to a promoter; b) transfecting in vitro a population o cultured cells with the recombinant vector, resulting in a population of the cultured cells; and c) transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes prevention o degeneration of the nerve.
(FR)L'invention concerne un procédé destiné à la prévention de la dégénérescence des nerfs, procédé comprenant les étapes suivantes : a) génération d'un vecteur viral ou plasmide recombinant comprenant une séquence ADN codant un élément d'une superfamille de croissance transformant ou des protéines d'un facteur neurotrophique liées coopérantes à un promoteur ; b) transfection in vitro d'une population de cellules cultivées avec le vecteur recombinant, conduisant à l'obtention d'une population de cellules cultivées ; et c) transplantation des cellules transfectées en une aire voisine du nerf lésé, de sorte que l'expression de la séquence ADN dans ladite aire voisine du nerf lésé entraîne la prévention de la dégénérescence du nerf.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)